EFCAB13 and myeloid sarcoma: We focused on the seven ASEs that have not yet been previously studied in the samples of MS patients according to our recent systematic review (49), i.e., for CLEC16A, the alternative 5’ donor site and the alternative last exon, exon skipping for EFCAB13 and TSFM, and intron retention for HLA-C and NCAPH2 (Table 1).